Month: April 2024

–Record annual revenue increased 85.3% year-over-year to $17.6 million in 2023 –Loan Book Value increased 194.2% to $55.6 million in 2023, up from $18.9 million year-over-year –Has facilitated more than $21.5 billion in deposit activity across 41 states since inception GOLDEN, Colo., April 01, 2024 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a/ Safe Harbor Financial (“Safe Harbor” or the “Company”) (NASDAQ: SHFS), a leader in facilitating financial services and credit facilities to the regulated cannabis industry, announced today its financial results for the fourth quarter and full year ended December 31, 2023. Full-Year 2023 Financial & Operational HighlightsRevenue increased 85.3% to $17.6 million, compared to $9.5 million for the full year of 2022; Loan Book Value at the end of 2023 increased 194.2%...

Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update. Fourth Quarter 2023 and Subsequent HighlightsMarch 2024: Significantly strengthened the company’s intellectual property portfolio related to an intragastric balloon system. Specifically, it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application...

CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights:Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow. The Continuing Operations focuses on the implementation of the business model to shift to solely support the manufacturing and distribution of Medtronic’s left-heart access product portfolio. Discontinued Operations relates to the Company’s mapping and ablation business that was wound down as part of the strategic realignment of resources and corporate restructuring. Fourth quarter revenue from Continuing Operations of $2.4 million grew 118%...

FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results. TOMI Chief Executive Officer, Dr. Halden Shane, stated, “During 2023 we continued to expand our sales infrastructure through the broadening of our distribution network, diversify our product line to support our growing customer base and the related utilization of our SteraMist technology and deliver multiple custom engineered systems to key customers. “We remain focused on expanding our internal and external sales infrastructure and business development initiatives. Last year we onboarded...

– Company demonstrates improved performance with record revenue and operating income in fiscal year 2023 – – Q4 2023 revenue of $24.2 million excluding discontinued operations increased 34.4% year-over-year – – Q4 2023 operating income of $5.4 million, the second consecutive quarter above $5 million – MINNEAPOLIS, April 01, 2024 (GLOBE NEWSWIRE) — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today reported financial results for its fourth quarter and full year ended December 31, 2023. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses...

-Project Continued Growth from Sales of AmnioWrap2®– -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem, commented, “BioStem had an outstanding fourth quarter. Revenue reached $11.5 million, nearly 14 times higher than revenue of roughly $0.8 million for last year’s comparable quarter. This growth was driven by the successful commercial launch into the private office setting of AmnioWrap2, our innovative placental-derived allograft...

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activated IL-12 Anticipates cash runway into the second quarter of 2025 WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) —  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023. “With our recently announced partnership with Gilead for XTX301, our tumor-activated...

LOUISVILLE, Ky., April 01, 2024 (GLOBE NEWSWIRE) — LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems, health communications devices, and technology for the growing care economy, today announced that it has postponed the release of fourth-quarter and full-year 2023 financial results, and the conference call originally scheduled for April 1, 2024. The Company is filing an extension with the SEC to allow for more time to complete its 2023 Annual Report on Form 10-K. For more information, please visit https://investors.logicmark.com/ for all of the company’s press releases and SEC filings, as well as the eCommerce site at https://www.logicmark.com/. About UsLogicMark, Inc. (Nasdaq: LGMK) provides personal emergency response systems (PERS), health communications devices, and technologies to create a Connected...

-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. “In 2023 we successfully executed our plan and achieved several key milestones that position Yield10 to build a sustainable products business based on engineered Camelina,” said Oliver...